60 million new autoimmune drugs purchased by Xinji Baijian

Source: Biovalley, September 11, 2015 news: a few months ago, celgene's acquisition of receptos attracted widespread attention in the industry Xinji acquired the San Diego based biomedical company for $7.2 billion to acquire the autoimmune disease drug ozanimod This drug is believed to play an important role in the treatment of autoimmune diseases such as multiple sclerosis and inflammatory enteritis Naturally, this news also made Biogen not calm down It's just the side of the so-called couch, how can others sleep? In order to compete with the new base in this field, Baijian recently said that the company has signed a cooperative R & D agreement with Japanese company Mitsubishi Tanabe Pharma to jointly develop the new autoimmune disease drug mt-1303 According to Baijian, the company has paid $60 million in advance to Mitsubishi Tanabe Pharma in exchange for the right to sell the drug in the world except for the Asian market In addition, the milestone bonus for the entire agreement is as high as $484 million At present, the drug has completed the mid-term clinical study of multiple sclerosis Baijian hopes that mt-1303 can open the markets of multiple sclerosis, inflammatory enteritis and ulcerative colitis in the future In addition, the clinical phase III study of mt-1303 in treating Crohn's disease is also under consideration Baijian has been enjoying a lot recently In March, the latest clinical research data of aducanumab, a new Alzheimer's drug developed by the company, helped the company's share price soar from $300 to $475 However, with the sluggish performance of its multiple sclerosis drug, dimetry fumarate (tecfidera), the company's share price quickly fell to $308 Therefore, the company urgently needs to find a new drug that can carry its banner in the field of autoimmune diseases Previously, it was reported that Baijian also participated in the acquisition of receptos, but as the latter finally fell in love with the new base, the company also changed its strategy rapidly and placed its hope on the mt-1301 In fact, the company is full of confidence in this drug CMO Alfred sandrock believes that mt-1301 will be the best S1P modulator drug This agreement also means that the race between Baijian and Xinji officially begins Xinji will complete the clinical phase III study of ozanimod in the treatment of multiple sclerosis in 2017, and will obtain the clinical phase III study data of ulcerative colitis the next year At present, the second phase clinical study of mt-1301 in the treatment of ulcerative colitis is in progress Therefore, some analysts believe that mt-1301 is more than two years behind ozanimod If Baijian wants to catch up, it may need more efforts.